Psilocybin for Alcoholism: Clinical Evidence, Trials & How It Works
Alcohol use disorder affects 29 million Americans. Standard treatments — naltrexone, CBT, AA — achieve long-term abstinence in roughly 20–30% of cases. A 2022 double-blind RCT found psilocybin therapy reduced heavy drinking days by 83%. Here is what the evidence actually says.
What the Research Shows
In the largest psilocybin-AUD trial to date (NYU/JHU, 2022, n=93), psilocybin therapy reduced heavy drinking days by 83% vs. 51% in the active placebo group, and achieved 48% total abstinence vs. 24% in controls — at 32-week follow-up.
Alcohol use disorder (AUD) is one of the leading causes of preventable death worldwide, responsible for approximately 95,000 deaths in the United States annually. Despite decades of research, the standard toolkit — motivational interviewing, cognitive behavioral therapy, naltrexone, acamprosate, and disulfiram — leaves the majority of patients without durable recovery. Long-term abstinence rates with pharmacotherapy alone remain in the 10–30% range at one year.
Psilocybin-assisted therapy represents a fundamentally different approach. Rather than targeting the pharmacology of cravings on a daily basis, it works through a concentrated therapeutic intervention — typically one or two high-dose sessions embedded within a framework of preparation and integration therapy — that catalyzes psychological change durable enough to sustain behavior change for months afterward.
The first modern pilot study, conducted at the University of New Mexico in 2012 (Bogenschutz et al.), enrolled 10 participants with AUD in a non-randomized open-label design. Participants showed significant decreases in drinking days and increases in abstinence at 36-week follow-up, with outcomes correlating with the intensity of the mystical experience during the psilocybin session. While small and uncontrolled, this study established the feasibility and safety profile that justified the larger trials that followed.
Psilocybin is not a daily medication. The therapeutic work happens in one to two intensive sessions, with durable outcomes lasting months — a fundamentally different model from conventional AUD pharmacotherapy.
How Psilocybin Works on Alcohol Dependence
Psilocybin disrupts the default mode network, stimulates neuroplasticity and BDNF, and creates a window of psychological flexibility so people can re-evaluate their relationship with alcohol. The intensity of the mystical experience predicts long-term drinking outcomes.
Psilocybin's mechanism of action in alcohol use disorder is not fully elucidated, but converging neuroscience and psychological research points to several overlapping pathways:
Default Mode Network Disruption
The default mode network (DMN) — a collection of midline brain structures including the medial prefrontal cortex, posterior cingulate cortex, and precuneus — is chronically overactive in both depression and addiction. In AUD, the DMN maintains entrenched drinking-related self-narratives ("I am a drinker"), catastrophizing rumination, and habitual craving cycles. Psilocybin produces a dose-dependent decrease in DMN activity and connectivity, temporarily dissolving these rigid patterns and creating a state of psychological openness that, with skilled therapeutic support, can enable people to rewrite their relationship with alcohol.
Neuroplasticity and BDNF
Psilocybin activates the 5-HT2A serotonin receptor in the prefrontal cortex, stimulating dendritic spine growth and synaptic remodeling — processes collectively termed neuroplasticity. Animal studies have shown that psilocybin increases brain-derived neurotrophic factor (BDNF), a protein critical for forming new neural pathways. This biological window of heightened plasticity may explain why the therapeutic gains from a single psilocybin session can persist for months: the session opens a neurological opportunity to establish new patterns of thought and behavior that then consolidate in subsequent integration therapy.
The Mystical Experience and Behavior Change
One of the most replicated and counterintuitive findings in psilocybin research is that the magnitude of the acute mystical or peak experience — characterized by feelings of unity, sacredness, noetic quality, and transcendence of time and space (assessed via the Mystical Experience Questionnaire) — independently predicts long-term behavioral outcomes. In the University of New Mexico AUD pilot, participants who reported more intense mystical experiences at their psilocybin session showed greater reductions in drinking at 36-week follow-up. A similar correlation was found in the 2022 NYU/JHU RCT. This suggests the psychological depth of the experience, not just the pharmacology, is doing therapeutic work.
Increased Global Brain Entropy
Neuroimaging studies show that psilocybin transiently increases global brain entropy — a measure of the complexity and unpredictability of brain signal patterns. Higher entropy correlates with a brain that is more flexible and less constrained by habitual networks. For people with AUD, whose reward circuits have been progressively narrowed by chronic alcohol exposure toward compulsive drinking behavior, this entropic opening may be the neurobiological correlate of the fresh perspective that many participants report: a sudden ability to see their drinking and their life from an entirely new vantage point.
Psilocybin does not chemically block cravings. It appears to catalyze psychological transformation by disrupting entrenched neural patterns, stimulating neuroplasticity, and enabling — via profound subjective experience — a fundamental re-evaluation of the person's identity and relationship to alcohol.
Clinical Trial Evidence
The 2022 NYU/Johns Hopkins double-blind RCT (n=93) is the definitive study: 83% fewer heavy drinking days and 48% abstinence at 32 weeks. Earlier pilots and ongoing Phase II trials support the same direction of effect.
| Study | Design | n | Key Finding | Evidence |
|---|---|---|---|---|
| Bogenschutz et al. (2015) Univ. New Mexico | Open-label pilot | 10 | Significant decrease in drinking days; effect size correlated with mystical experience intensity | Pilot |
| Bogenschutz et al. (2022) NYU / Johns Hopkins | Double-blind RCT | 93 | 83% reduction in heavy drinking days vs. 51% placebo; 48% abstinence vs. 24% at 32 weeks | RCT |
| Bathje et al. (ongoing) UCSF / JHU COMBINE | Phase II RCT | ~200 | Ongoing; testing psilocybin + naltrexone vs. psilocybin alone vs. naltrexone alone | Ongoing |
| Carhart-Harris et al. (2021) Imperial College | fMRI neuroimaging | — | Identifies DMN disruption and increased global brain entropy as key neurobiological correlates of psilocybin's therapeutic action | Mechanistic |
The 2022 NYU/Johns Hopkins RCT in Depth
Published in JAMA Psychiatry, this is the definitive study to date. 93 adults with DSM-5 alcohol use disorder (moderate to severe) were randomized to receive two sessions of either pharmaceutical psilocybin (25–40 mg/70 kg) or an active placebo (diphenhydramine 50 mg), both delivered with identical 12-session motivational enhancement therapy. Participants, therapists, and outcome assessors were all blinded. The primary outcome was percentage of heavy drinking days during weeks 25–32 post-session.
The psilocybin group showed 83% fewer heavy drinking days vs. baseline, compared to 51% in the placebo group — a statistically significant and clinically meaningful difference. 48% of psilocybin recipients were completely abstinent at follow-up, double the 24% abstinence rate in the control group. Crucially, no serious adverse events were attributed to psilocybin, reinforcing its safety profile in a screened clinical population under supervised conditions.
Psilocybin does not currently hold FDA Breakthrough Therapy designation for AUD specifically. However, the 2022 JAMA Psychiatry RCT has been recognized as a landmark dataset that may support an IND (Investigational New Drug) application and eventual FDA review. Multiple Phase II/III trials are currently recruiting. Check ClinicalTrials.gov with the search term "psilocybin alcohol" for currently enrolling studies.
The 2022 NYU/JHU RCT is the strongest evidence to date: double-blind, active placebo, 93 participants, with 83% reduction in heavy drinking days and 48% abstinence at 32 weeks.
Psilocybin vs. Standard AUD Medications
Psilocybin uses 1–2 sessions with durable effect; naltrexone and acamprosate require daily dosing with ~15–25% abstinence at one year. No head-to-head RCTs exist yet.
| Factor | Psilocybin Therapy | Naltrexone | Acamprosate | Disulfiram |
|---|---|---|---|---|
| Dosing frequency | 1–2 sessions total | Daily (oral) or monthly (injectable) | 3× daily | Daily |
| Abstinence rates (1-year) | ~48% (32-wk RCT data) | ~15–25% | ~14–20% | Variable; adherence-dependent |
| Mechanism | Neuroplasticity + psychological | Opioid receptor blockade | GABA/glutamate modulation | Acetaldehyde aversion |
| Legal status (US) | OR + CO only (facilitated) | FDA-approved | FDA-approved | FDA-approved |
| Major contraindications | Personal/family psychosis hx; lithium | Active hepatic disease; opioid dependence | Severe renal impairment | Cardiovascular disease; psychosis hx |
It bears emphasis that psilocybin and pharmacotherapy are not mutually exclusive. The UCSF COMBINE trial is explicitly testing psilocybin in combination with naltrexone. The therapeutic framework that surrounds psilocybin sessions — motivational enhancement therapy, integration counseling — also has independent evidence of effectiveness. The combination of pharmacological and psychological mechanisms may ultimately prove synergistic.
Psilocybin offers a different treatment model: 1–2 sessions with months of benefit, versus daily medication with modest long-term abstinence rates. Combination with naltrexone is under study.
What the Treatment Protocol Involves
All clinical protocols use three phases: preparation (2–4 sessions), one or two psilocybin sessions in a supervised setting, and integration (4–8 sessions). Total span is typically 10–14 weeks.
Psilocybin-assisted therapy for AUD is not a recreational or self-directed experience. All clinical protocols share a three-phase structure:
Phase 1: Preparation (2–4 sessions)
Before any psilocybin is administered, participants complete multiple preparatory therapy sessions with their treatment team. These sessions establish a therapeutic alliance, explore the individual's relationship with alcohol and their motivations for change, address expectations and anxieties about the psilocybin experience, and develop an intention for the session. Physical and psychiatric screening is completed at this stage, including review of medications, cardiovascular status, and mental health history. The quality of preparation is consistently identified as a moderator of outcomes.
Phase 2: Psilocybin Sessions (1–2 sessions)
Sessions take place in a carefully designed, comfortable environment — not a clinical hospital room but a purpose-designed space with soft lighting, music, comfortable furniture, and two trained guides or therapists present throughout. The participant typically lies down, wears eyeshades, and listens to a curated music program. The dose ranges from 25–40 mg/70 kg in clinical trials, producing a full psychedelic experience lasting 4–6 hours. Guides do not direct the experience but provide a safe, supportive presence and gentle anchoring if distress arises. The experience often includes profound emotional insights, visual phenomena, feelings of connectedness, and confrontation with suppressed material related to alcohol use and identity.
Phase 3: Integration (4–8 sessions)
The days and weeks following a psilocybin session are the integration period — when the insights and experiences from the session are processed, consolidated, and translated into concrete behavioral changes. Integration sessions are not optional. The quality of integration therapy appears to significantly moderate how durably the psilocybin session changes behavior. See our guide to psilocybin therapy for a detailed breakdown of the three-phase model.
Acute alcohol withdrawal carries serious medical risk, including seizures and delirium tremens. Anyone with significant physical alcohol dependence must undergo medically supervised detox before participating in any psilocybin protocol. Do not attempt to self-administer psilocybin as a substitute for medical withdrawal management.
Preparation, dosing session(s), and integration are all essential. Withdrawal must be managed medically before any psilocybin session.
Who Qualifies — and Who Doesn't
Good candidates: adults with moderate-to-severe AUD who have tried standard treatments, are medically stable and not in withdrawal, without psychosis/bipolar I/family history, and willing to complete the full protocol. Contraindications include psychosis risk, lithium, severe cardiovascular disease, active suicidality, pregnancy.
Likely Good Candidates
- Adults with diagnosed moderate-to-severe AUD who have attempted and not responded to standard treatments (CBT, naltrexone, acamprosate, AA)
- Individuals who are medically stable and not in active alcohol withdrawal
- People without a personal or family history of psychotic spectrum disorders (schizophrenia, schizoaffective disorder, bipolar I)
- Individuals willing to commit to the full protocol — preparation, sessions, and integration — which typically spans 10–14 weeks total
- People with a support network or willing to engage one during the integration period
Contraindications
- Personal or family history of schizophrenia, schizoaffective disorder, or bipolar I — psilocybin can precipitate or worsen psychosis in at-risk individuals
- Current lithium use — co-administration with psilocybin has been associated with seizure risk in case reports
- Severe cardiovascular disease or uncontrolled hypertension — psilocybin transiently elevates heart rate and blood pressure
- Active suicidal ideation — acute crisis requires direct psychiatric intervention, not psychedelic therapy
- Pregnancy — safety data are absent; all trials exclude pregnant participants
Note that many standard AUD medications (SSRIs, benzodiazepines) may need to be adjusted or tapered before a psilocybin session under medical supervision. SSRIs blunt psilocybin's effect by downregulating 5-HT2A receptors. Always disclose all medications to the treating team during screening.
Medical and psychiatric screening is required. Psychosis risk, lithium, severe cardiovascular disease, and active withdrawal are absolute contraindications.
How to Access Psilocybin Treatment for Alcoholism in 2026
Clinical trials (ClinicalTrials.gov) offer the most rigorous access. Oregon and Colorado permit licensed facilitated sessions for adults 21+ without a diagnosis. International retreats exist in the Netherlands, Jamaica, and Mexico.
Clinical Trials (United States)
The most rigorous route to access is via a clinical trial. Multiple Phase II trials are recruiting participants with AUD as of 2026. Go to ClinicalTrials.gov and search for "psilocybin alcohol use disorder" to find currently enrolling studies near you. Participants typically receive the full treatment protocol at no cost and make a meaningful contribution to the evidence base.
Oregon Psilocybin Service Centers
Oregon's Measure 109 framework, which became operational in June 2023, permits adults 21+ to access psilocybin in licensed service centers with a trained facilitator, without a medical diagnosis requirement. This means people with AUD can access psilocybin-assisted experiences in Oregon without needing a formal clinical referral. Costs typically range from $500–$3,000 per session when combined with preparation and integration services. See our retreats directory for vetted Oregon options.
Colorado Natural Medicine Health Act
Colorado's Amendment 58 framework began licensing healing centers for psilocybin services in June 2025. Similar to Oregon, adults 21+ can access supervised psilocybin without a medical diagnosis. Costs and availability are still scaling as the licensing infrastructure matures.
International Options
Psilocybin retreats in the Netherlands (legal psilocybin truffles), Jamaica (unscheduled), and Mexico (unscheduled) are operating and accessible to international visitors. These vary significantly in clinical rigor, screening protocols, and integration support. Prioritize retreat providers who conduct psychiatric screening, have trained facilitators, and include integration follow-up. Review our retreat guide before booking any international program. Also check our legal status guide for jurisdiction-specific details.
Access routes: clinical trials (strongest), Oregon and Colorado service centers, and vetted international retreats. Always verify legal status and provider quality.
Safety Profile and Risks
No serious adverse events have been attributed to psilocybin in published AUD trials. Common effects include transient anxiety, nausea, and elevated heart rate during the session. Withdrawal must be managed medically before any protocol.
Across all published clinical trials of psilocybin in AUD, no serious adverse events have been attributed to psilocybin itself. The most common side effects during sessions include:
- Transient anxiety or fear during the experience (most common; manageable with guide support)
- Nausea (10–20% of participants; usually mild and time-limited)
- Elevated heart rate and blood pressure during the session (screened for in all trials)
- Headache in the 24 hours following the session
Psychological risks — including challenging or difficult experiences — are present but are significantly mitigated by careful screening, set and setting, and trained guide presence. Hallucinogen persisting perception disorder (HPPD) is theoretically possible but has not been reported in any clinical trial of psilocybin administered in controlled conditions. The physiological toxicity of psilocybin is extremely low; there are no documented cases of lethal overdose from psilocybin alone. For a full breakdown of effects and risks, see our effects guide and our safe trip guide.
If you or someone you know is in a medical emergency related to alcohol use, call 911 or go to the nearest emergency room. Psilocybin is not a crisis intervention tool and is never appropriate in the context of acute intoxication or withdrawal.
In screened, supervised settings, psilocybin has a strong safety profile. Acute withdrawal and emergencies require medical care first.
Key Takeaways
- ✓ The 2022 JAMA Psychiatry double-blind RCT (n=93) found psilocybin therapy reduced heavy drinking days by 83% and achieved 48% total abstinence at 32 weeks — roughly double placebo outcomes.
- ✓ Psilocybin appears to work via DMN disruption, neuroplasticity stimulation, and profound psychological experiences that break habitual drinking patterns.
- ✓ The magnitude of the acute mystical experience correlates with long-term drinking outcomes — psychological depth of the session predicts behavioral change.
- ✓ Treatment involves a three-phase protocol: preparation (2–4 sessions), one or two psilocybin sessions, and integration therapy (4–8 sessions) over approximately 10–14 weeks total.
- ✓ Legal supervised access is available in Oregon and Colorado; clinical trials are recruiting nationally.
- ✓ People with personal or family history of psychosis, bipolar I, or who are on lithium are contraindicated.
- ✓ Acute alcohol withdrawal is a medical emergency requiring supervised medical management before any psilocybin protocol.
Frequently Asked Questions
Related Resources
For the full therapeutic protocol and how to find a provider, see our psilocybin therapy guide. For evidence across other substance use disorders, see Psilocybin for Addiction. For legal retreat options, see our retreats directory and legal status guide. For harm reduction and support, see our safe trip guide and trip sitter guide.